|
Baseline Clinical Characteristics of Study Patients |
|||
| All Patients |
Trimetazidine |
Placebo |
|
|
|
|||
| Mean age (years) |
65.4 ± 6.3 |
65.6 ± 5.7 |
65.2 ± 7 |
| Male |
24 |
11 |
13 |
| Female |
8 |
5 |
3 |
| BMI |
25.4 ± 3.2 |
25.7 ± 3.3 |
25.2 ± 3.3 |
| Baseline glucose |
164.6 ± 26.2 |
166.9 ± 21.9 |
162.2 ± 30.4 |
| Triglycerides at baseline |
238.1 ± 59.5 |
231.3 ± 43.7 |
244.9 ± 72.9 |
| Triglycerides at randomisation |
185.7 ± 46.4 |
180.5 ± 34 |
191 ± 57 |
| Cholesterol at baseline |
264.5 ± 27.8 |
263.3 ± 29.3 |
265.2 ± 27.2 |
| Cholesterol at randomisation |
198.3 ± 20.8 |
197.8 ± 21.9 |
198.8 ± 20.4 |
| HBA1c |
7.6 ± 0.8 |
7.7 ± 1 |
7.5 ± 0.6 |
| Prior MI |
18 |
9 |
9 |
| Prior CABG |
7 |
4 |
3 |
| Prior PTCA |
12 |
6 |
8 |
| Carotid Atherosclerosis |
12 |
7 |
5 |
| Coronary atherosclerosis |
|||
| 1 vessel disease |
1 |
0 |
1 |
| 2 vessel disease |
14 |
6 |
8 |
| 3 vessel disease |
16 |
9 |
7 |
| any vessel + graft |
1 |
1 |
0 |
| distal disease |
23 |
12 |
11 |
| USE OF DRUGS AT RANDOMISATION |
|||
| Aspirin/ticlopidine |
18 |
12 |
14 |
| Clopidogrel |
6 |
6 |
4 |
| Anticoagulants |
6 |
5 |
6 |
| Digitalis |
28 |
13 |
15 |
| Diuretics |
31 |
16 |
15 |
| Nitrates |
18 |
8 |
10 |
| B-blockers |
23 |
11 |
12 |
| Ca-antagonists |
14 |
9 |
6 |
| ACE-I |
29 |
14 |
15 |
| ARB |
4 |
2 |
2 |
| Statins |
30 |
14 |
16 |
| Oral hypoglycaemics |
25 |
12 |
13 |
| Insulin |
7 |
4 |
3 |
|
Clinical features of study patients. Clinical characteristics, incidence of previous myocardial infarction or revascularization procedures in patients randomized to trimetazidine or placebo. No significant differences were detected between groups. BMI = body mass index, MI = myocardial infarction, CABG = coronary artery by-pass grafting, PC I = percutaneous coronary interventions. | |||
Rosano et al. Cardiovascular Diabetology 2003 2:16 doi:10.1186/1475-2840-2-16 |
|||